Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

ESMO open·2026
Same author

Resting-state functional connectivity and cognitive impairment after COVID-19 infection: Evidence from a large-scale fMRI study.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Clinical terminology and biological mediators in allergology: why biomarkers do not define a syndrome.

European annals of allergy and clinical immunology·2026
Same author

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

ESMO open·2026
Same author

READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.

ESMO real world data and digital oncology·2026
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

ESMO open·2025

Related Experiment Video

Updated: May 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

New agents for prostate cancer.

N Agarwal1, G Di Lorenzo2, G Sonpavde3

  • 1Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|March 25, 2014
PubMed
Summary

Recent advances have revolutionized metastatic castration-resistant prostate cancer (mCRPC) treatment with novel agents like immunotherapy and androgen axis inhibitors, extending survival. Further research into new targets and resistance mechanisms is crucial for improved outcomes.

Keywords:
novel agentsprostate cancer

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: May 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has rapidly evolved with new drug approvals.
  • Several novel therapeutic agents have demonstrated incremental survival benefits in mCRPC patients.

Purpose of the Study:

  • To review the current and emerging therapeutic options for mCRPC.
  • To highlight the challenges and future directions in mCRPC treatment.

Main Methods:

  • Literature review of recent clinical trials and studies on mCRPC therapeutics.
  • Analysis of novel agents targeting androgen pathways, immunotherapy, and molecular drivers.
  • Discussion of resistance mechanisms and biomarker development.

Main Results:

  • Approved agents include sipuleucel-T, abiraterone acetate, enzalutamide, cabazitaxel, and radium-223.
  • Emerging therapies include novel androgen pathway inhibitors, immunotherapies (e.g., ipilimumab), and targeted biologics (e.g., cabozantinib).
  • Combinations with docetaxel have shown mixed results, with ongoing trials for agents like custirsen.

Conclusions:

  • The armamentarium against mCRPC continues to expand with promising new agents.
  • Key challenges include identifying new targets, understanding resistance, optimizing treatment sequencing, and developing predictive biomarkers.
  • Enrollment in clinical trials and deeper biological understanding are essential for advancing mCRPC care.